Nanobiotix (NASDAQ: NBTX) updates share capital and voting rights figures

Rhea-AI Filing Summary

Nanobiotix S.A. filed an update on its share capital and voting rights. As of February 28, 2026, the company had 48,494,528 shares outstanding, with 50,197,214 total theoretical voting rights and 50,175,096 exercisable voting rights, reflecting French regulatory disclosure requirements for threshold calculations.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On March 12, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated March 12, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: March 12, 2026		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

EXHIBIT 99.1

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, March 12, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
February 28, 2026	48,494,528	50,197,214	50,175,096

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

________________________________

¹ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Attachment

• 2026-03-12 -- NBTX -- Voting Rights & Shares Capital -- FINAL (https://ml.globenewswire.com/Resource/Download/a8a8b1de-10a2-4aaa-a9e5-329a08c09522)

FAQ

What voting rights did Nanobiotix (NBTX) report as of February 28, 2026?

Nanobiotix reported 50,197,214 total theoretical voting rights and 50,175,096 exercisable voting rights as of February 28, 2026. Theoretical rights include all shares with attached votes, while exercisable rights exclude shares with suspended voting rights such as treasury stock.

How many Nanobiotix (NBTX) shares were outstanding on February 28, 2026?

Nanobiotix had 48,494,528 shares outstanding on February 28, 2026. This figure underpins the calculation of the company’s voting rights and is used in France to monitor shareholding thresholds and related disclosure obligations for investors crossing ownership levels.

Why does Nanobiotix (NBTX) disclose theoretical and exercisable voting rights?

Nanobiotix discloses both theoretical and exercisable voting rights in line with French Commercial Code and AMF rules. Theoretical rights support threshold-crossing calculations, while exercisable rights show votes that can be cast at shareholder meetings, excluding shares with suspended voting rights such as treasury shares.

On which markets is Nanobiotix (NBTX) listed?

Nanobiotix is listed on Euronext Paris in Compartment B and on the Nasdaq Global Select Market under the ticker NBTX. These dual listings provide access to both European and U.S. investors and are referenced in the company’s share capital and voting rights disclosure.

What type of company is Nanobiotix (NBTX)?

Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France. It focuses on physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms addressing oncology, bioavailability and biodistribution, and central nervous system disorders.

Which French regulations govern Nanobiotix (NBTX) voting rights disclosure?

Nanobiotix’s voting rights and share capital disclosure follows Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. These rules require regular publication of outstanding shares and voting rights to keep the market properly informed.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 7.5 KB